SiriusPoint Non-GAAP EPS of $0.88 beats by $0.24, revenue of $867.6M beats by $84.53M (NYSE:SPNT)

SiriusPoint reported Q3 Non-GAAP EPS of $0.88, exceeding estimates by $0.24, with revenue of $867.6M, up 14.8% year-over-year and beating expectations by $84.53M. The company's shares rose 1.74% following the earnings release.

Original reporting
Published Nov 5, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SPNT
Bullish
high confidence
Mentioned
$SPNT
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SPNTBullishHigh
01

Why it matters

The earnings beat could trigger short-covering and attract new buying interest.

02

Market read

Earnings beat provides a fresh catalyst for SPNT, likely driving short-term price upside.

03

What to watch

Potential impact of upcoming regulatory changes on underwriting profitability.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

SiriusPoint is a specialty insurer and reinsurer listed on NYSE under SPNT.

Company-level read

Ticker impact

$SPNTBullishHigh confidence
Context

SiriusPoint reported Q3 Non-GAAP EPS of $0.88, beating expectations by $0.24 and revenue of $867.6M, up 14.8% YoY and $84.53M above forecasts.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded consensus, and the stock already rose 1.74% on the news.

Market effects

Positive signal for the specialty insurance sector, may lift peers.

U.S. market focus, limited regional effect.

Modest, confined to insurance and reinsurance investors.

Counterpoint

Some analysts may question sustainability of growth given higher expense base.

Key entities

  • SiriusPoint Ltd.

    Specialty insurer reporting Q3 results.

Related articles

$SPNTMed

Oppenheimer raises SiriusPoint stock price target on earnings beat

Oppenheimer raised its price target on SiriusPoint Ltd (NYSE: SPNT) to $31 from $27, citing strong Q3 2026 earnings. The company reported adjusted earnings of $0.74 per share, beating estimates, with revenue of $867.6 million. Oppenheimer updated its 2026 EPS estimate to $2.83 and introduced a 2028 estimate of $2.90, excluding one-time costs. SiriusPoint's core combined ratio remained steady at 90.1%.

$SPNTMed

SiriusPoint Q3 Earnings Call Highlights

SiriusPoint (SPNT) reported Q3 earnings, with insurance premiums up 20% and reinsurance down 6%. The company expects to complete a transaction by Q4 2023 or Q1 2024, with $74M remaining for share repurchases. Core underwriting income rose 22% to $202M. SiriusPoint plans to restructure its reporting segments and anticipates modest growth in 2027.

$SPNTMedAI 8/10

SiriusPoint (SPNT) Q3 2026 Earnings Call Transcript

SiriusPoint (SPNT) reported Q3 2026 earnings, highlighting 20% growth in insurance and services, a core combined ratio of 90.1%, and an operating return on equity of 17.6%. The company also announced a loss portfolio transfer agreement to reduce legacy runoff exposures, freeing up over $200 million in capital. Year-to-date, insurance and services grew by 14%, with a core combined ratio of 90.1% and an operating return on equity of 15.8%.

MedAI 8/10

SiriusPoint run-off deal expected to release $200m

SiriusPoint announced a deal to release $200M in capital via a loss portfolio transfer with RiverStone. Q3 net income was $87M, down from $90.7M YoY, but operating net income rose to $103.2M. Core gross written premiums grew 13.7% to $990.6M, with Insurance & Services driving growth. CEO Scott Egan highlighted 17.6% operating returns on equity, exceeding targets.